CoChat

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients

Open access
Marcq, Elly, Waele, Jorrit De, Audenaerde, Jonas Van, Lion, Eva, Santermans, Eva, Hens, Niel, Pauwels, Patrick, van Meerbeeck, Jan P., Smits, Evelien L.J. · 2017 · Oncotarget
Cited by 57

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Elly Marcq 1 , Jorrit De Waele 1 , Jonas Van Audenaerde 1 , Eva Lion 2 , Eva Santermans 3 , Niel Hens 3, 4 , Patrick Pauwels 1, 5 , Jan P. van Meerbeeck 1, 6, * and Evelien L.J. Smits 1, 2, * 1 Center for Oncological Research, University of Antwerp, Antwerp, Belgium 2 Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium 3 Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium 4 Center for Health Economics Research and Modelling Infectious Diseases, University of Antwerp, Antwerp, Belgium 5 Department of Pathology, Antwerp University Hospital, Antwerp, Belgium 6 Thoracic Oncology/MOCA, Antwerp University Hospital, Antwerp, Belgium * Shared senior authors Correspondence to: Elly Marcq, email: Elly.Marcq@uantwerpen.be Keywords: mesothelioma, immune checkpoints, effusions, tumor microenvironment, flow cytometry Received: April 21, 2017 Accepted: September 01, 2017 Published: September 21, 2017 ABSTRACT Malignant pleural mesothelioma (MPM) is an aggressive cancer with an increasing incidence, poor prognosis and limited effective treatment options. Hence, new treatment strategies are warranted which include immune checkpoint blockade approaches with encouraging preliminary data. Research on the immunological aspects of the easily accessible mesothelioma microenvironment could identify prognostic and/or predictive biomarkers and provide useful insights for developing effective immunotherapy. In this context, we investigated the immune cell composition of effusions (pleural and ascites fluids) from 11 different chemotherapy-treated MPM patients. We used multicolor flow cytometry to describe different subsets of immune cells and their expression of immune checkpoint molecules TIM-3, LAG-3, PD-1 and PD-L1. We demonstrate a patient-dependent inter- and intraspecific variation comparing pleural and ascites fluids in immune cell composition and immune checkpoint expression. We found CD4 + and CD8 + T cells, B cells, macrophages, natural killer cells, dendritic cells and tumor cells in the fluids. To the best of our knowledge, we are the first to report TIM-3 and LAG-3 expression and we confirm PD-1 and PD-L1 expression on different MPM effusion-resident immune cells. Moreover, we identified two MPM effusion-related factors with clinical value: CD4+ T cells were significantly correlated with better response to chemotherapy, while the percentage of PD-L1 + podoplanin (PDPN) + tumor cells is a significant prognostic factor for worse outcome. Our data provide a basis for more elaborate research on MPM effusion material in the context of treatment follow-up and prognostic biomarkers and the development of immune checkpoint-targeted immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.21113

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Marcq, E., Waele, J. D., Audenaerde, J. V., Lion, E., Santermans, E., Hens, N., Pauwels, P., van Meerbeeck, J. P., & Smits, E. L. J.
Venue
Oncotarget
Published
2017-09-21
Volume
8
Issue
52
Pages
89722-89735
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2758966180
Cited by
57
References
5
FWCI
3.24
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.